Cancer Risk Management Decision Making for BRCA+ Women

Western Journal of Nursing Research

Volumn 37, Issue 1, 2015, Pages 66-84

  Leonarczyk, Terri Jabaley ^a   Mawn, Barbara E ^b  

^a EMMANUEL COLLEGE   (United States)

^b UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

Author keywords

BRCA; genetics genomics; oncology; phenomenology; qualitative

Indexed keywords

ADULT; BREAST NEOPLASMS; DECISION MAKING; FEMALE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PROCEDURES; QUALITATIVE RESEARCH; RISK MANAGEMENT; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; DECISION MAKING; FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; QUALITATIVE RESEARCH; RISK MANAGEMENT;

EID: 84912058951     PISSN: 01939459     EISSN: 15528456     Source Type: Journal    
DOI: 10.1177/0193945913519870     Document Type: Article

References (45)

1. Antoniou A.,Pharoah P.,Narod S.,Risch H. A.,Eyfjord J. E.,Hopper J. L.,.. Easton D. F.Average risks of breast and ovarian cancer associated with BRCA 1 and BRCA 2 mutations detected in case series unselected for family history: A combined analysis of 22 studies.American Journal of Human Genetics. 2003;72:1117-1130
2. Armstrong K.,Schwartz J. S.,Randall T.,Rubin S. C.,Weber B.Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: A decision analysis.Journal of Clinical Oncology. 2004;22:1045-1054
3. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 12–398
4. Balmana J.,Diez O.,Rubio I.,Castiglione M.BRCA in breast cancer: ESMO clinical practice guidelines.Annals of Oncology. 2010;21:v20-v22
5. Berliner J. L.,Fay A. M.Risk assessment and genetic counseling for hereditary breast and ovarian cancer: Recommendations of the National Society of Genetic Counselors.Journal of Genetic Counseling. 2007;16:241-260
6. Chen W. Y.,Garber J. E.,Highman S.,Schneider K. A.,Davis K. B.,Deffenbaugh A. M.,.. Li F. P.BRCA1/2 genetic testing in the community setting.Journal of Clinical Oncology. 2002;20:4485-4492
7. Croster C. B.,Dickerson S. S.Women receiving news of a family BRCA 1/2 mutation: Messages of fear and empowerment.Journal of Nursing Scholarship. 2010;42:367-378
8. den Heijer M.,Vos J.,Seynaeve C.,Vanheusden K.,Duivenvoorden H. J.,Tilanus-Linthorse M.,.. Tibben A.The impact of social and personal resources on psychological distress in women at risk for hereditary breast cancer.Psycho-Oncology. 2012;21:153-160
9. Finch A.,Metcalf K. A.,Chiang J. K.,Elit L.,McLaughlin J.,Springate C.,.. Narod S. A.The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.Gynecologic Oncology. 2011;121:163-168
10. Halbert C. H.,Stopfer J. E.,McDonald J.,Weathers B.,Collier A.,Troxel A. B.,Domcheck S.Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: Does time heal women’s concerns?.Journal of Clinical Oncology. 2011;29:4302-4306
11. Hallowell N.,Jacobs I.,Richards M.,Mackay J.,Gore M.Surveillance or surgery? A description of the factors that influence high risk premenopausal women’s decisions about prophylactic oophorectomy.Journal of Medical Genetics. 2001;38:683-726
12. Hamilton R.Nursing advocacy in a postgenomic age.Nursing Clinics of North America. 2009;44:435-446
13. Hamilton R.Being young, female, and BRCA positive.American Journal of Nursing. 2012;112:26-31
14. Hamilton R.,Hurley K. E.Conditions and consequences of a BRCA mutation in young, single women of childbearing age.Oncology Nursing Forum. 2010;37:627-634
15. Hamilton R.,Williams J. K.,Bowers B. J.,Calzone K.Life trajectories, genetic testing, and risk reduction decisions in 18-39 year old women at risk for hereditary breast and ovarian cancer.Journal of Genetic Counseling. 2009;18:147-159
16. Hamilton R.,Williams J. K.,Skirton H.,Bowers B. J.Living with genetic test results for hereditary breast and ovarian cancer.Journal of Nursing Scholarship. 2009;41:276-283
17. Iodice S.,Barile M.,Rotmensz N.,Feroc I.,Bonanni B.,Radice P.,.. Gandini S.Oral contraceptive use and breast or ovarian cancer risk in BRCA 1/2 carriers: A meta-analysis.European Journal of Cancer. 2010;46:2275-2284
18. Jenkins J.,Calzone K. A.,Dimond E.,Liewehr D. J.,Steinberg S. M.,Jourkiv O.,.. Kirsch I. R.Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic testing result disclosure.Genetics in Medicine. 2007;9:487-495
19. Kenen R. H.,Shapiro P. J.,Friedman S.,Coyne J.Peer support in coping with medical uncertainty: Discussion of oophorectomy and hormone replacement therapy on a web-based message board.Psycho-Oncology. 2007;16:763-771
20. King M.,Wieand S.,Hale K.,Lee M.,Walsh T.,Owens K.,.. Fisher B.Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA 1 and BRCA 2.Journal of the American Medical Association. 2001;286:2251-2256
21. Kurian A. W.,Sigal B. M.,Plevritis S. K.Survival analysis of cancer risk reduction strategies for BRCA 1/2 mutation carriers.Journal of Clinical Oncology. 2010;28:222-231
22. Loescher L. J.,Lim K. H.,Leitner O.,Ray J.,D’Souza J.,Armstrong C. M.Cancer surveillance behaviors in women presenting for clinical BRCA genetic susceptibility testing.Oncology Nursing Forum. 2009;36:E57-E67
23. Lynch H. T.,Snyder C. L.,Lynch J. F.,Riley B. D.,Rubinstein W. S.Hereditary breast-ovarian cancer at the bedside: Role of the medical oncologist.Journal of Clinical Oncology. 2003;21:740-753
24. Metcalfe K. A.,Foulkes W. D.,Kim-Sing C.,Ainsworth P.,Rosen B.,Armel S.,.. Narod S. A.Family history as a predictor of uptake of cancer prevention procedures by women with a BRCA1 or BRCA2 mutation.Clinical Genetics. 2008;73:474-479
25. Metcalfe K. A.,Poll A.,O’Connor A.,Gershman S.,Armel S.,Finch A.,.. Narod S. A.Development and testing of a decision aid for breast cancer prevention for women with a BRCA 1 or BRCA 2 mutation.Clinical Genetics. 2007;72:208-217
26. Metcalfe K. A.,Snyder C.,Seidel J.,Hanna D.,Lynch H.,Narod S.The use of preventative measures among healthy women who carry a BRCA1 or BRCA2 mutation.Familial Cancer. 2005;4:97-103
27. Moustakas C.Phenomenological research methods. Thousand Oaks, CA: SAGE; 1994:
28. Myriad. (2011, July29). Myriad applauds the court of appeals’ decision to uphold gene patenting. Retrieved from http://investor.myriad.com/releasedetail.cfm?ReleaseID=595288
29. National Cancer Institute. (2013). Genetics of breast and ovarian cancer. Retrieved from http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/healthprofessional/
30. National Comprehensive Cancer Network. (2013). NCCN clinical practice guidelines in oncology (NCCN GuidelinesTM) Genetic/familial high-risk assessment: Breast and ovarian version 4. Retrieved from http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf
31. Phillips K. A.,Jenkins M. A.,Lindeman G. J.,McLachlan S. A.,McKinley J. M.,Weideman P. C.,.. Friedlander M. L.Risk-reducing surgery, screening and chemoprevention practices of BRCA 1 and BRCA 2 mutation carriers: A prospective cohort study.Clinical Genetics. 2006;70:198-206
32. Rebbeck T.,Kauff N. D.,Domchek S. M.Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.Journal of the National Cancer Institute. 2009;101:80-87
33. Rice L. W.Hormone prevention strategies for breast, endometrial and ovarian cancers.Gynecologic Oncology. 2010;118:202-207
34. Samuel J. C.,Ollila D. W.Prophylaxis and screening options: Recommendations for young women with BRCA mutations.Breast Disease. 2005-2006;23:31-35
35. Schwartz M. D.,Kaufman E.,Peshkin B. N.,Isaacs C.,Hughes C.,DeMarco T.,.. Lerman C.Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA 1/BRCA 2 mutation testing.Journal of Clinical Oncology. 2003;21:4034-4041
36. Schwartz M. D.,Peshkin B. N.,Tercyak K. P.,Taylor K. L.,Valdimarsdottir H.Decision making and decision support for hereditary breast-ovarian cancer susceptibility.Health Psychology. 2005;24:S78-S84
37. Skirton H.,O’Connor A.,Humphreys A.Nurses’ competence in genetics: A mixed method systematic review.Journal of Advanced Nursing. 2012;68:2387-2398
38. Snyder C.,Lynch J.,Lynch H.Genetic counseling and the advanced practice oncology nursing role in a hereditary cancer prevention clinic: Hereditary breast cancer focus (part I).Breast Journal. 2009;15:2-10
39. van Oostrom I.,Meijers-Heijboer H.,Lodder L. N.,Duivenvoorden H. J.,van Gool A. R.,Seynaeve C.,.. Tibben A.Long-term psychological impact of carrying a BRCA 1/2 mutation and prophylactic surgery: A 5-year follow-up study.Journal of Clinical Oncology. 2003;21:3867-3874
40. Welcsh P. L.,King M. C.BRCA 1 and BRCA 2 and the genetics of breast and ovarian cancer.Human Molecular Genetics. 2001;10:705-713
41. Werner-Lin A.Beating the biological clock: The compressed family life cycle of young women with BRCA gene alterations.Social Work in Health Care. 2008a;47:416-437
42. Werner-Lin A.Formal and informal support needs of young women with BRCA mutations.Journal of Psychosocial Oncology. 2008b;26:111-133
43. Werner-Lin A.,Hoskins L.,Doyle M. H.,Green M. H.Cancer doesn’t have an age: Genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24.Health. 2012;16:636-654
44. Werner-Lin A.,Rubin L. R.,Doyle M.,Stern R.,Savin K.,Hurley K.,Sagi M.My funky genetics: BRCA1/2 mutation carriers’ understanding of genetic inheritance and reproductive merger in the context of new reprogenetic technologies.Families, Systems, & Health. 2012;30:166-180
45. Whittemore A. S.,Balise R. R.,Pharoan P. D.,DiCioccio R. A.,Oakley-Girvan I.,Ramus S. J.,.. Piver M. S.Oral contraceptive use and ovarian cancer risk among carriers of BRCA 1 or BRCA 2 mutations.British Journal of Cancer. 2004;91:1911-1915